75 results on '"Nadal, E."'
Search Results
2. P2.10A.07 Trofuse-009: Phase 3 Study of Sac-TNT vs Platinum-Doublet Chemotherapy for Previously Treated EGFR-Mutated Advanced NSCLC.
3. MA12.08 Preventing Infusion-Related Reactions with Intravenous Amivantamab: Primary Results from SKIPPirr, a Phase 2 Study.
4. MA01.08 Five-Year Clinical Outcomes of Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer (NADIM Trial).
5. PL04.04 Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC.
6. P3.08E.04 TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials.
7. MA16.04 Circulating Tumor DNA Quantification by NGS Should Be Adapted to the Methodology Used.
8. SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020).
9. Topology and shape optimization of dissipative and hybrid mufflers.
10. In situ synthesis of gold nanoparticles in polymer films under concentrated sunlight: control of nanoparticle size and shape with solar flux.
11. EP08.03-01 Copy Number Variants and Late Somatic Mutations Underlying Tumor Progression in NADIM Clinical Trials.
12. P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy.
13. XVI Reunión Nacional de Geomorfología Zaragoza (6-8 septiembre 2023) "Aprendiendo del pasado proyectando hacia el futuro".
14. 187P Tissue B-cell receptor repertoire as biomarker of complete pathological response in NSCLC patients treated with neoadjuvant chemoimmunotherapy (NADIM trials).
15. Estimating the Relative Stiffness between a Hepatic Lesion and the Liver Parenchyma through Biomechanical Simulations of the Breathing Process.
16. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
17. EP16.03-027 Routine Molecular Testing Using the TSO500+ NGS Panel in a Cohort of Patients with NSCLC.
18. EP08.01-090 Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront.
19. EP08.01-029 NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases.
20. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study.
21. OA02.03 Tumor Bulk-RNA Seq Identifies Patients at High Risk of Progression in Non-complete Pathological Responders from NADIM Trial.
22. Fundaments of Recovery-Based Error Estimation and Bounding.
23. Plasmon-enhanced diffraction in nanoparticle gratings fabricated by in situ photo-reduction of gold chloride doped polymer thin films by laser interference patterning.
24. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015.
25. High-resolution thermal analysis at thermoplastic pre-impregnated acomposite interfaces.
26. EP08.01-091 Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront.
27. P2.14-04 Re-Definition of Lung Adenocarcinoma Transcriptional Subtypes Using Integrative Bioinformatics Approaches.
28. P1.09-03 Multidisciplinary Thoracic Tumors Board Survey in Spain.
29. MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial.
30. OA07.06 Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC).
31. P50.01 RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19-del Variants.
32. P47.09 Tepotinib + Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2.
33. OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy.
34. A separated representation of an error indicator for the mesh refinement process under the proper generalized decomposition framework.
35. Imposing Dirichlet boundary conditions in hierarchical Cartesian meshes by means of stabilized Lagrange multipliers.
36. Mesh adaptivity driven by goal-oriented locally equilibrated superconvergent patch recovery.
37. P60.11 TCR Repertoire Predicts Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemoimmunotherapy from NADIM Trial.
38. MA01.06 Phase 2 of Pro-Autophagic Drug ABTL0812 in Combination With First-Line Paclitaxel and Carboplatin in IIIb/IV Squamous NSCLC.
39. FP12.09 Molecular Insight into NADIM Clinical Trial: Potential Immune Biomarkers of Pathological Response for NSCLC Patients.
40. FP07.06 Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront.
41. Efficient Finite Element Methodology Based on Cartesian Grids: Application to Structural Shape Optimization.
42. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy.
43. Temporal variability in the relationships between precipitation, discharge and suspended sediment concentration in a small Mediterranean mountain catchment.
44. Factors for graft- versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose.
45. Increased frequencies of CD4+CD25high Tregs correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
46. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma.
47. Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies.
48. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission.
49. Smoldering multiple myeloma: natural history and recognition of an evolving type.
50. Serial quantification of lymphoid and myeloid mixed chimerism using multiplex PCR amplification of short tandem repeat-markers predicts graft rejection and relapse, respectively, after allogeneic transplantation of CD34+ selected cells...
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.